Identification and characterization of M6903, an antagonistic anti–TIM-3 monoclonal antibody

References

• Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415(536–541). doi:10.1038/415536a.
   PubMedGoogle Scholar
• Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207(2175–2186). doi:10.1084/jem.20100637.
   Google Scholar
• Yan J, Xu H, Yan Q, Yang S, Duan X, Jiang Z. Tim-3 expression defines regulatory T cells in human tumors. PLoS One. 2013;8(e58006). doi:10.1371/journal.pone.0058006.
   Google Scholar
• Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276(97–111). doi:10.1111/imr.12520.
   PubMedGoogle Scholar
• Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(1245–1252). doi:10.1038/ni1271.
   Google Scholar
• Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, Azuma M, Yagita H, Okumura K. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood. 2009;113(3821–3830). doi:10.1182/blood-2008-10-185884.
   Google Scholar
• Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, Dougan SK, Petersen B-S, Melum E, Pertel T. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015;517(386–390). doi:10.1038/nature13848.
   Google Scholar
• Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan JD. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(832–842). doi:10.1038/ni.2376.
   PubMedGoogle Scholar
• Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(2187–2194). doi:10.1084/jem.20100643.
   PubMedGoogle Scholar
• Sakuishi K, Ngiow SF, Sullivan JM, Teng MWL, Kuchroo VK, Smyth MJ, Anderson AC. TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2013;2(e23849). doi:10.4161/onci.23849.
   PubMedGoogle Scholar
• Dardalhon V, Anderson AC, Karman J, Apetoh L, Chandwaskar R, Lee DH, Cornejo M, Nishi N, Yamauchi A, Quintana FJ. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol. 2010;185(1383–1392). doi:10.4049/jimmunol.0903275.
   PubMedGoogle Scholar
• Sabatos-Peyton CA, Nevin J, Brock A, Venable JD, Tan DJ, Kassam N, Xu F, Taraszka J, Wesemann L, Pertel T. Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy. Oncoimmunology. 2018;7(e1385690). doi:10.1080/2162402x.2017.1385690.
   PubMedGoogle Scholar
• Goncalves Silva I, Rüegg L, Gibbs BF, Bardelli M, Fruehwirth A, Varani L, Berger SM, Fasler-Kan E, Sumbayev VV. The immune receptor Tim-3 acts as a trafficker in a Tim-3/galectin-9 autocrine loop in human myeloid leukemia cells. Oncoimmunology. 2016;5(e1195535). doi:10.1080/2162402x.2016.1195535.
   PubMedGoogle Scholar
• Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117(4501–4510). doi:10.1182/blood-2010-10-310425.
   Google Scholar
• Taghiloo S, Singh G, Mahapatra M, Kumar L, Chandra NC. Upregulation of Galectin-9 and PD-L1 immune checkpoints molecules in patients with chronic lymphocytic leukemia. Asian Pacific J Cancer Preven. 2017;18(2269–2274). doi:10.22034/apjcp.2017.18.8.2269.
   PubMedGoogle Scholar
• Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MWL, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011;71(3540–3551). doi:10.1158/0008-5472.CAN-11-0096.
   Google Scholar
• Su H, Xie H, Dai C, Ren Y, She Y, Xu L, Chen D, Xie D, Zhang L, Jiang G. Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma. Lung Cancer. 2018;121(18–24). doi:10.1016/j.lungcan.2018.04.009.
   PubMedGoogle Scholar
• Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7(10501). doi:10.1038/ncomms10501.
   Google Scholar
• Harding JJ, Patnaik A, Moreno V, Stein M, Jankowska AM, Velez de Mendizabal N, Tina Liu Z, Koneru M, Calvo E. Abstract 12: A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): interim safety, efficacy, and pharmacokinetic findings in advanced cancers. J Clin Oncol. 2019:37. doi:10.1200/JCO.2019.37.8_suppl.12.
   Web of Science ®Google Scholar
• Davar D, Boasberg PD, Eroglu Z, Falchook GS, Gainor JF, Hamilton EP, Hecht JR, Luke JJ, Pishvaian M, Ribas A, et al. Abstract O21: A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma. J Immuno Therapy Cancer. 2018;6(Suppl 1):155. doi:10.1186/s40425-018-0423-x.
   Google Scholar
• Curigliano G, Gelderblom H, Mach N, Doi T, Tai W, Forde P, Sarantopoulos J, Bedard P, Lin C-C, Hodi S, et al. Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies. Cancer Res. 2019;79(13 Suppl):CT183. doi:10.1158/1538-7445.AM2019-CT183.
   Web of Science ®Google Scholar
• Isshiki T, Akiba H, Nakayama M, Harada N, Okumura K, Homma S, Miyake S. Cutting edge: anti-TIM-3 treatment exacerbates pulmonary inflammation and fibrosis in mice. J Immunol. 2017;199(3733–3737). doi:10.4049/jimmunol.1700059.
   PubMedGoogle Scholar
• Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, Yu H, Qin G, Sircar A, Hernández VM. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Transl Med. 2018;10(eaan5488). doi:10.1126/scitranslmed.aan5488.
   PubMedGoogle Scholar
• Karsunky HJ, Jiang Y-P. Antibodies that specifically bind to Tim3. United States patent US 8,841,418 B2. 2014.
   Google Scholar
• Sabatos-Peyton CA, Brannetti B, Harris AS, Huber T, Pietzonka T, Mataraza JM, Blattler WA, Hicklin DJ, Vasquez M, DeKruyff RH, et al. Antibody molecules to tim-3 and uses thereof. United States patent US2015/0218274 A1. 2015.
   Google Scholar
• Feldman I, Novobrantseva T, Wong J, Phennicie R, Sazinsky S, Sathyanarayanan S Antibodies that inhibit tim-3: LILRB2Interactions and uses thereof. United States patent US 2016/0200815 A1. 2016.
   Google Scholar
• DeKruyff RH, Bu X, Ballesteros A, Santiago C, Chim YLE, Lee -H-H, Karisola P, Pichavant M, Kaplan GG, Umetsu DT. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol. 2010;184(1918–1930). doi:10.4049/jimmunol.0903059.
   PubMedGoogle Scholar
• Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev. 2010;235(172–189). doi:10.1111/j.0105-2896.2010.00903.x.
   PubMedGoogle Scholar
• Chen Y, Xue S-A, Behboudi S, Mohammad GH, Pereira SP, Morris EC. Ex vivo PD-L1/PD-1 pathway blockade reverses dysfunction of circulating CEA-Specific T cells in pancreatic cancer patients. Clin Cancer Res. 2017;23(6178–6189). doi:10.1158/1078-0432.CCR-17-1185.
   Google Scholar
• Liu J, Zhao X, Li Z, Qi G. Targeting PD-1 and tim-3 pathways to reverse CD8 T-cell exhaustion and enhance ex vivo T-cell responses to autologous dendritic/tumor vaccines. J Immunother (Hagerstown, Md.: 1997). 2016;39(171–180). doi:10.1097/cji.0000000000000122.
   Google Scholar
• Lu X, Yang L, Yao D, Wu X, Li J, Liu X, Deng L, Huang C, Wang Y, Li D. Tumor antigen-specific CD8(+) T cells are negatively regulated by PD-1 and Tim-3 in human gastric cancer. Cell Immunol. 2017;313(43–51). doi:10.1016/j.cellimm.2017.01.001.
   PubMedGoogle Scholar
• Cao E, Zang X, Ramagopal UA, Mukhopadhaya A, Fedorov A, Fedorov E, Zencheck WD, Lary JW, Cole JL, Deng H. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity. 2007;26(311–321). doi:10.1016/j.immuni.2007.01.016.
   Google Scholar
• Gandhi AK, Kim WM, Sun ZYJ, Huang Y-H, Bonsor DA, Sundberg EJ, Kondo Y, Wagner G, Kuchroo VK, Petsko G. High resolution X-ray and NMR structural study of human T-cell immunoglobulin and mucin domain containing protein-3. Sci Rep. 2018;8(17512). doi:10.1038/s41598-018-35754-0.
   Google Scholar
• Clayton KL, Haaland MS, Douglas-Vail MB, Mujib S, Chew GM, Ndhlovu LC, Ostrowski MA. T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases. J Immunol. 2014;192(782–791). doi:10.4049/jimmunol.1302663.
   Google Scholar
• Goncalves Silva I, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Bardelli M, Varani L, Hussain R, Siligardi G, Ceccone G. The tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine. 2017;22(44–57). doi:10.1016/j.ebiom.2017.07.018.
   PubMedGoogle Scholar
• Golden-Mason L, McMahan RH, Strong M, Reisdorph R, Mahaffey S, Palmer BE, Cheng L, Kulesza C, Hirashima M, Niki T. Galectin-9 functionally impairs natural killer cells in humans and mice. J Virol. 2013;87(4835–4845). doi:10.1128/jvi.01085-12.
   PubMedGoogle Scholar
• Kikushige Y, Miyamoto T, Yuda J, Jabbarzadeh-Tabrizi S, Shima T, Takayanagi S-I, Niiro H, Yurino A, Miyawaki K, Takenaka K. A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell. 2015;17(341–352). doi:10.1016/j.stem.2015.07.011.
   PubMedGoogle Scholar
• Prokhorov A, Gibbs BF, Bardelli M, Rüegg L, Fasler-Kan E, Varani L, Sumbayev VV. The immune receptor Tim-3 mediates activation of PI3 kinase/mTOR and HIF-1 pathways in human myeloid leukaemia cells. Int J Biochem Cell Biol. 2015;59(11–20). doi:10.1016/j.biocel.2014.11.017.
   PubMedGoogle Scholar
• Delaine T, Collins P, MacKinnon A, Sharma G, Stegmayr J, Rajput VK, Mandal S, Cumpstey I, Larumbe A, Salameh BA. Galectin-3-binding glycomimetics that strongly reduce bleomycin-induced lung fibrosis and modulate intracellular glycan recognition. Chembiochem. 2016;17(1759–1770). doi:10.1002/cbic.201600285.
   PubMedGoogle Scholar
• Nielsen MI, Stegmayr J, Grant OC, Yang Z, Nilsson UJ, Boos I, Carlsson MC, Woods RJ, Unverzagt C, Leffler H. Galectin binding to cells and glycoproteins with genetically modified glycosylation reveals galectin-glycan specificities in a natural context. J Biol Chem. 2018;293(20249–20262). doi:10.1074/jbc.RA118.004636.
   Google Scholar
• Haidar JN, Antonysamy S, Mathew S, Wu L, Zhang Y, Kearins MC, Shen L, Sauder JM, Schaer D, Driscoll KE, et al. Abstract 2753: the molecular basis of blocking the TIM-3 checkpoint with the LY3321367 mAb in cancer immunotherapy. Cancer Res. 2019;79(2753–2753). doi:10.1158/1538-7445.am2019-2753.
   Google Scholar
• Fujita T, Burwitz BJ, Chew GM, Reed JS, Pathak R, Seger E, Clayton KL, Rini JM, Ostrowski MA, Ishii N. Expansion of dysfunctional Tim-3–expressing effector memory CD8+ T cells during simian immunodeficiency virus infection in rhesus macaques. J Immunol. 2014;193(5576–5583). doi:10.4049/jimmunol.1400961.
   PubMedGoogle Scholar
• Amancha PK, Hong JJ, Ansari AA, Villinger F. Up-regulation of Tim-3 on T cells during acute simian immunodeficiency virus infection and on antigen specific responders. AIDS. 2015;29(531–536). doi:10.1097/QAD.0000000000000589.
   PubMedGoogle Scholar